What is Dimerix?
Founded in 2004 and headquartered in Australia, Dimerix is dedicated to creating innovative treatments for global markets. The company's core focus lies in its proprietary product, DMX-200, which is being developed for Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). Dimerix leverages its unique Receptor Heteromer Investigation Technology (Receptor-HIT) platform, a scalable technology designed to understand receptor interactions and rapidly identify new drug opportunities. This platform has been licensed non-exclusively to Excellerate Bioscience, a recognized provider of pharmacological assay services.
How much funding has Dimerix raised?
Dimerix has raised a total of $28.7M across 2 funding rounds:
Share Placement
$20M
Other Financing Round
$8.7M
Share Placement (2021): $20M with participation from Peter Meurs and Merchant Funds Management
Other Financing Round (2023): $8.7M led by Mercer Street Partners
Key Investors in Dimerix
Merchant Funds Management
Merchant Funds Management is an Australian investment firm established in 2011, specializing in tailored investment management services for high-net-worth clients. Led by investment manager Andrew Chapman, the firm focuses on active portfolio management and risk assessment, aiming to outperform market benchmarks.
Mercer Street Partners
Mercer Street Partners is a real estate investment and asset management firm that employs institutional-level acquisition tactics for middle-market transactions. The firm's management team has extensive experience in acquiring and managing diverse real estate assets, focusing on disciplined capital deployment and active asset management.
What's next for Dimerix?
The recent major strategic investment signals a pivotal growth phase for Dimerix, likely positioning the company for further clinical development and potential commercialization of DMX-200. This capital infusion is anticipated to bolster research and development efforts, potentially expanding the scope of clinical trials and advancing the company's therapeutic candidates through regulatory pathways. Dimerix's strategic focus on leveraging its Receptor-HIT platform suggests a continued emphasis on innovation and the identification of new drug opportunities, aiming to solidify its market position in the biopharmaceutical sector.
See full Dimerix company page
